Table 3.
Changes in intestinal permeability following treatment with lumiracoxib and diclofenac
| Treatment | 51Cr-EDTA excretion in urine (%) | ||||
|---|---|---|---|---|---|
| Single dose | Four doses | ||||
| 30 mg kg−1 | 3 mg kg−1 | 10 mg kg−1 | 30 mg kg−1 | 100 mg kg−1 | |
| Lumiracoxib | 2.5±0.2* (n=18) | nt | 1.8±0.2* (n=12) | 4.3±0.4** (n=15) | 31.3±3.2** (n=9) |
| Diclofenac | 12.7±1.4** (n=24) | 5.0 ±1.1**> (n=12) | 12.8±1.5** (n=29) | nt | nt |
Rats were given test compound or vehicle – either in a single dose or once daily for 4 consecutive days. Immediately following the last dose, each rat was administered 5 μCi of 51Cr-EDTA. The level of 51Cr-EDTA was then measured in urine collected over a 24-h period.
*
Results shown are means±s.e.m. (n), where n=number of rats per dose. The % permeability for the vehicle-treated rats was 1.9±0.1 (24) in the single-dose study and 1.59±0.06 (51) in the four-dose group.
**
*P<0.05 vs diclofenac-treated rats; **P<0.05 vs vehicle-treated rats; nt=not tested.